Morgan Stanley
SHPH icon

Morgan Stanley’s Shuttle Pharmaceuticals SHPH Stock Holding History

Morgan Stanley’s Portfolio SHPH Stock Details SHPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18 Hold
3
– – ﹤0.01% 8177
2025
Q4 		$49 Hold
3
– – ﹤0.01% 7864
2025
Q3 		$96 Buy
+3
New +$112 ﹤0.01% 7691

Other funds holding SHPH

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
KFA
Kelleher Financial Advisors New York $395M AUM 12.89% 1-Year Est. Return

Morgan Stanley's SHPH Position: Q1 2026 in Review

Morgan Stanley held its Shuttle Pharmaceuticals (SHPH) position steady in Q1 2026 at 3 shares worth $18. The position accounts for ﹤0.01% of the portfolio, ranked #8177.

Morgan Stanley first reported a position in SHPH in Q3 2025 and has held it in 3 quarters since. The position peaked at $96 in Q3 2025. 8 funds tracked by Wall St. Rank hold SHPH as of Q1 2026.

  • Morgan Stanley held 3 shares of Shuttle Pharmaceuticals worth $18 as of Q1 2026.
  • Morgan Stanley left its Shuttle Pharmaceuticals share count unchanged in Q1 2026.
  • Shuttle Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #8177 holding.
  • Morgan Stanley first reported a position in Shuttle Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Morgan Stanley's Shuttle Pharmaceuticals position peaked at $96 in Q3 2025.
  • 8 funds tracked by Wall St. Rank held Shuttle Pharmaceuticals as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.